Crossmark

The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation

Crossref DOI link: https://doi.org/10.1038/s41401-018-0043-5

Published Online: 2018-06-21

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

He, Jun

Gao, Hao-xue

Yang, Na

Zhu, Xiao-dong

Sun, Run-bin

Xie, Yuan

Zeng, Cai-hong

Zhang, Jing-wei

Wang, Jian-kun

Ding, Fei

Aa, Ji-ye

Wang, Guang-ji
License Information

Text and Data Mining valid from 2018-06-21
More Information

Article History

Received: 10 January 2018

Accepted: 17 April 2018

First Online: 21 June 2018

Competing interests

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.